Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Sequenom grosses $51.6 million for diagnostics development: Firm will gross $51.6 million through the sale of 12.4 million shares of its stock at $4.15 each to "certain investors" under an agreement announced May 12. The private placement is expected to close May 17. Proceeds will be used for R&D and product commercialization efforts. The San Diego firm says it expects launch a noninvasive, laboratory-developed DNA test for Down syndrome (Trisomy 21) by the end of 2011 and file a PMA application for the test by the end of 2012. Sequenom also is aiming to launch a laboratory-developed test for age-related macular degeneration in the first half of 2011. Jefferies & Company and Lazard Capital Markets were placement agents for the stock offering

You may also be interested in...

Robotic knee surgery

Curexo Technology submits 510(k) application for use of its Robodoc robotic surgical system to prepare knee joints for replacement. Robodoc allows surgeons to preoperatively plan total knee arthroplasty procedures in a 3-D virtual space and then perform the surgery exactly as planned on the patient's knee. The robotic surgical system gained 510(k) clearance for use in total hip arthroplasty in August and has been used in over 24,000 surgical procedures worldwide to date (1"The Gray Sheet" Aug. 25, 2008, In Brief)

Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies

A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts